Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy
Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy
Recruiting · NCT07240844 · Registry updated 2026-06-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy | Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, familial amyloid neuropathy, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, proteostasis deficiencies | Recruiting | Phase 4 | 2026-06-18 | NCT07240844 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Samsung Medical Center | 207 |
| Seoul St. Mary's Hospital | 31 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Samsung Medical Center | Seoul | South Korea | 375 |
| Seoul St. Mary's Hospital, The Catholic University of Korea | Seoul | South Korea | 5 |